Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) represent the standard therapeutic modality for patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations (Soria et al., 2018; Hsu et al., 2018). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.